Search results
Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move...
Zacks via Yahoo Finance· 1 week agoThe consensus price target hints at a 69.2% upside potential for Fulcrum Therapeutics (FULC). While...
Here's Why Fulcrum Therapeutics, Inc. (FULC) is Poised for a Turnaround After Losing 32.6% in 4...
Zacks via Yahoo Finance· 2 years agoFulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies...
Are You Looking for a Top Momentum Pick? Why Fulcrum Therapeutics, Inc. (FULC) is a Great Choice
Zacks via Yahoo Finance· 1 year agoMomentum investing revolves around the idea of following a stock's recent trend in either direction....
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) institutional owners may be pleased with recent gains after...
Simply Wall St. via Yahoo Finance· 3 months agoKey Insights Significantly high institutional ownership implies Fulcrum Therapeutics' stock price is...
Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks via Yahoo Finance· 2 years agoFulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a...
Investors in Fulcrum Therapeutics (NASDAQ:FULC) have unfortunately lost 61% over the last year
Simply Wall St. via Yahoo Finance· 1 year agoEven the best stock pickers will make plenty of bad investments. And there's no doubt that Fulcrum...
Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate
Zacks via Yahoo Finance· 9 months agoFulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its...
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance· 2 years agoFulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -25.76% and 28.98%,...
CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock
Simply Wall St. via Yahoo Finance· 3 months agoInvestors who take an interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) should definitely note...
Time To Worry? Analysts Just Downgraded Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Outlook
Simply Wall St. via Yahoo Finance· 2 years agoToday is shaping up negative for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) shareholders, with the...